Nicotinamide improves glucose metabolism and affects the hepatic NAD-sirtuin pathway in a rodent model of obesity and type 2 diabetes

Journal of Nutritional Biochemistry

Volumn 25, Issue 1, 2014, Pages 66-72

  Yang, Soo Jin ^a   Choi, Jung Mook ^b   Kim, Lisa ^b   Park, Se Eun ^b   Rhee, Eun Jung ^b   Lee, Won Young ^b   Oh, Ki Won ^b   Park, Sung Woo ^b   Park, Cheol Young ^b  

^a Chonnam National University   (South Korea)

^b Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

NAD; Nicotinamide; Nicotinic acid; PGC 1 alpha; Sirtuin

Indexed keywords

ADIPONECTIN; GLUCOSE; INSULIN; MESSENGER RNA; MITOCHONDRIAL DNA; NICOTINAMIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; NICOTINIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; SIRTUIN; SIRTUIN 1; SIRTUIN 2; SIRTUIN 3; SIRTUIN 4; SIRTUIN 5; SIRTUIN 6; SIRTUIN 7;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DRUG EFFICACY; FLUID INTAKE; FOOD INTAKE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLYCEMIC CONTROL; HOMEOSTASIS; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID DIET; LIVER LEVEL; MALE; METABOLIC REGULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OTSUKA LONG EVANS TOKUSHIMA FATTY RAT; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RAT; SIGNAL TRANSDUCTION; WEIGHT CHANGE;

NAD; NICOTINAMIDE; NICOTINIC ACID; PGC-1 ALPHA; SIRTUIN;

ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; DIET, HIGH-FAT; DISEASE MODELS, ANIMAL; DNA, MITOCHONDRIAL; ENERGY METABOLISM; GLUCOSE; GLUCOSE TOLERANCE TEST; INSULIN RESISTANCE; LIVER; MALE; MITOCHONDRIAL TURNOVER; NAD; NIACINAMIDE; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; OBESITY; RATS; RATS, INBRED OLETF; SIGNAL TRANSDUCTION; SIRTUIN 1; SIRTUINS; TRANSCRIPTION FACTORS;

EID: 84889594248     PISSN: 09552863     EISSN: 18734847     Source Type: Journal    
DOI: 10.1016/j.jnutbio.2013.09.004     Document Type: Article

References (42)

1. Magni G., Amici A., Emanuelli M., Orsomando G., Raffaelli N., Ruggieri S. Enzymology of NAD+homeostasis in man. Cell Mol Life Sci 2004, 61:19-34.
2. Rongvaux A., Andris F., Van Gool F., Leo O. Reconstructing eukaryotic NAD metabolism. Bioessays 2003, 25:683-690.
3. Magni G., Amici A., Emanuelli M., Raffaelli N., Ruggieri S. Enzymology of NAD+synthesis. Adv Enzymol Relat Areas Mol Biol 1999, 73:135-182.
4. Revollo J.R., Grimm A.A., Imai S. The regulation of nicotinamide adenine dinucleotide biosynthesis by Nampt/PBEF/visfatin in mammals. Curr Opin Gastroenterol 2007, 23:164-170.
5. Revollo J.R., Grimm A.A., Imai S. The NAD biosynthesis pathway mediated by nicotinamide phosphoribosyltransferase regulates Sir2 activity in mammalian cells. J Biol Chem 2004, 279:50754-50763.
6. Haigis M.C., Guarente L.P. Mammalian sirtuins - emerging roles in physiology, aging, and calorie restriction. Genes Dev 2006, 20:2913-2921.
7. Pfluger P.T., Herranz D., Velasco-Miguel S., Serrano M., Tschop M.H. Sirt1 protects against high-fat diet-induced metabolic damage. Proc Natl Acad Sci U S A 2008, 105:9793-9798.
8. Xu F., Gao Z., Zhang J., Rivera C.A., Yin J., Weng J., et al. Lack of SIRT1 (Mammalian Sirtuin 1) activity leads to liver steatosis in the SIRT1+/- mice: a role of lipid mobilization and inflammation. Endocrinology 2010, 151:2504-2514.
9. Zhong L., D'Urso A., Toiber D., Sebastian C., Henry R.E., Vadysirisack D.D., et al. The histone deacetylase Sirt6 regulates glucose homeostasis via Hif1alpha. Cell 2010, 140:280-293.
10. Xiao C., Kim H.S., Lahusen T., Wang R.H., Xu X., Gavrilova O., et al. SIRT6 deficiency results in severe hypoglycemia by enhancing both basal and insulin-stimulated glucose uptake in mice. J Biol Chem 2010, 285:36776-36784.
11. Kanfi Y., Peshti V., Gil R., Naiman S., Nahum L., Levin E., et al. SIRT6 protects against pathological damage caused by diet-induced obesity. Aging Cell 2010, 9:162-173.
12. Kendrick A.A., Choudhury M., Rahman S.M., McCurdy C.E., Friederich M., Van Hove J.L., et al. Fatty liver is associated with reduced SIRT3 activity and mitochondrial protein hyperacetylation. Biochem J 2011, 433:505-514.
13. Palacios O.M., Carmona J.J., Michan S., Chen K.Y., Manabe Y., Ward J.L., et al. Diet and exercise signals regulate SIRT3 and activate AMPK and PGC-1alpha in skeletal muscle. Aging (Albany NY) 2009, 1:771-783.
14. Jing E., Gesta S., Kahn C.R. SIRT2 regulates adipocyte differentiation through FoxO1 acetylation/deacetylation. Cell Metab 2007, 6:105-114.
15. Krishnan J., Danzer C., Simka T., Ukropec J., Walter K.M., Kumpf S., et al. Dietary obesity-associated Hif1alpha activation in adipocytes restricts fatty acid oxidation and energy expenditure via suppression of the Sirt2-NAD+system. Genes Dev 2012, 26:259-270.
16. Yoshinari O., Igarashi K. Anti-diabetic effect of trigonelline and nicotinic acid, on KK-A(y) mice. Curr Med Chem 2010, 17:2196-2202.
17. Li H.M., Zhang M., Xu S.T., Li D.Z., Zhu L.Y., Peng S.W., et al. Nicotinic acid inhibits glucose-stimulated insulin secretion via the G protein-coupled receptor PUMA-G in murine islet beta cells. Pancreas 2011, 40:615-621.
18. Oh Y.T., Oh K.S., Choi Y.M., Jokiaho A., Donovan C., Choi S., et al. Continuous 24-h nicotinic acid infusion in rats causes FFA rebound and insulin resistance by altering gene expression and basal lipolysis in adipose tissue. Am J Physiol Endocrinol Metab 2011, 300:E1012-E1021.
19. Olmos P.R., Hodgson M.I., Maiz A., Manrique M., De Valdes M.D., Foncea R., et al. Nicotinamide protected first-phase insulin response (FPIR) and prevented clinical disease in first-degree relatives of type-1 diabetics. Diabetes Res Clin Pract 2006, 71:320-333.
20. Gale E.A., Bingley P.J., Emmett C.L., Collier T. European Nicotinamide Diabetes Intervention Trial (ENDIT): a randomised controlled trial of intervention before the onset of type 1 diabetes. Lancet 2004, 363:925-931.
21. Cabrera-Rode E., Molina G., Arranz C., Vera M., Gonzalez P., Suarez R., et al. Effect of standard nicotinamide in the prevention of type 1 diabetes in first degree relatives of persons with type 1 diabetes. Autoimmunity 2006, 39:333-340.
22. Liu D., Gharavi R., Pitta M., Gleichmann M., Mattson M.P. Nicotinamide prevents NAD+depletion and protects neurons against excitotoxicity and cerebral ischemia: NAD+consumption by SIRT1 may endanger energetically compromised neurons. Neuromolecular Med 2009, 11:28-42.
23. Kelly G. A review of the sirtuin system, its clinical implications, and the potential role of dietary activators like resveratrol: part 1. Altern Med Rev 2010, 15:245-263.
24. Bitterman K.J., Anderson R.M., Cohen H.Y., Latorre-Esteves M., Sinclair D.A. Inhibition of silencing and accelerated aging by nicotinamide, a putative negative regulator of yeast sir2 and human SIRT1. J Biol Chem 2002, 277:45099-45107.
25. Hou X., Xu S., Maitland-Toolan K.A., Sato K., Jiang B., Ido Y., et al. SIRT1 regulates hepatocyte lipid metabolism through activating AMP-activated protein kinase. J Biol Chem 2008, 283:20015-20026.
26. Avalos J.L., Bever K.M., Wolberger C. Mechanism of sirtuin inhibition by nicotinamide: altering the NAD(+) cosubstrate specificity of a Sir2 enzyme. Mol Cell 2005, 17:855-868.
27. Yang S.J., Choi J.M., Chae S.W., Kim W.J., Park S.E., Rhee E.J., et al. Activation of peroxisome proliferator-activated receptor gamma by rosiglitazone increases sirt6 expression and ameliorates hepatic steatosis in rats. PLoS One 2011, 6:e17057.
28. Picca A, Fracasso F, Pesce V, Cantatore P, Joseph AM, Leeuwenburgh C, et al. Age- and calorie restriction-related changes in rat brain mitochondrial DNA and TFAM binding. Age (Dordr) 2012. 2012 Sep 4. [Epub ahead of print].
29. Revollo J.R., Korner A., Mills K.F., Satoh A., Wang T., Garten A., et al. Nampt/PBEF/Visfatin regulates insulin secretion in beta cells as a systemic NAD biosynthetic enzyme. Cell Metab 2007, 6:363-375.
30. Imai S., Kiess W. Therapeutic potential of SIRT1 and NAMPT-mediated NAD biosynthesis in type 2 diabetes. Front Biosci 2009, 14:2983-2995.
31. Imai S., The N.A.D. World: a new systemic regulatory network for metabolism and aging-Sirt1, systemic NAD biosynthesis, and their importance. Cell Biochem Biophys 2009, 53:65-74.
32. Canto C., Houtkooper R.H., Pirinen E., Youn D.Y., Oosterveer M.H., Cen Y., et al. The NAD(+) precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet-induced obesity. Cell Metab 2012, 15:838-847.
33. Liu D., Pitta M., Jiang H., Lee J.H., Zhang G., Chen X., Kawamoto E.M., Mattson M.P. Nicotinamide forestalls pathology and cognitive decline in Alzheimer mice: evidence for improved neuronal bioenergetics and autophagy procession. Neurobiol Aging 2013, 34:1564-1580.
34. John C.M., Ramasamy R., Al Naqeeb G., Al-Nuaimi A.H., Adam A. Nicotinamide supplementation protects gestational diabetic rats by reducing oxidative stress and enhancing immune responses. Curr Med Chem 2012, 19:5181-5186.
35. Collins P.B., Chaykin S. The management of nicotinamide and nicotinic acid in the mouse. J Biol Chem 1972, 247:778-783.
36. Yoshino J., Mills K.F., Yoon M.J., Imai S. Nicotinamide mononucleotide, a key NAD(+) intermediate, treats the pathophysiology of diet- and age-induced diabetes in mice. Cell Metab 2011, 14:528-536.
37. Nemoto S., Fergusson M.M., Finkel T. SIRT1 functionally interacts with the metabolic regulator and transcriptional coactivator PGC-1{alpha}. J Biol Chem 2005, 280:16456-16460.
38. Arany Z., He H., Lin J., Hoyer K., Handschin C., Toka O., et al. Transcriptional coactivator PGC-1 alpha controls the energy state and contractile function of cardiac muscle. Cell Metab 2005, 1:259-271.
39. Czubryt M.P., McAnally J., Fishman G.I., Olson E.N. Regulation of peroxisome proliferator-activated receptor gamma coactivator 1 alpha (PGC-1 alpha) and mitochondrial function by MEF2 and HDAC5. Proc Natl Acad Sci U S A 2003, 100:1711-1716.
40. Olesen J., Kiilerich K., Pilegaard H. PGC-1alpha-mediated adaptations in skeletal muscle. Pflugers Arch 2010, 460:153-162.
41. Bieganowski P., Brenner C. Discoveries of nicotinamide riboside as a nutrient and conserved NRK genes establish a Preiss-Handler independent route to NAD+in fungi and humans. Cell 2004, 117:495-502.
42. Belenky P., Racette F.G., Bogan K.L., McClure J.M., Smith J.S., Brenner C. Nicotinamide riboside promotes Sir2 silencing and extends lifespan via Nrk and Urh1/Pnp1/Meu1 pathways to NAD+. Cell 2007, 129:473-484.